Levilimab
Levilimab is a monoclonal antibody used in the treatment of various inflammatory conditions. It is specifically designed to target and inhibit the activity of interleukin-6 (IL-6), a cytokine involved in the inflammatory response. By blocking IL-6, levilimab can reduce inflammation and modulate the immune system's activity.
Mechanism of Action[edit | edit source]
Levilimab works by binding to the IL-6 receptor, preventing IL-6 from exerting its effects on target cells. IL-6 is a pro-inflammatory cytokine that plays a crucial role in the immune response, particularly in the activation of T-cells and the production of acute phase proteins by the liver. By inhibiting IL-6, levilimab can decrease the inflammatory response and is useful in treating conditions characterized by excessive inflammation.
Clinical Uses[edit | edit source]
Levilimab is primarily used in the treatment of autoimmune diseases and inflammatory conditions such as rheumatoid arthritis and cytokine release syndrome. It may also be investigated for use in other conditions where IL-6 plays a significant role in pathogenesis.
Side Effects[edit | edit source]
Common side effects of levilimab include injection site reactions, upper respiratory tract infections, and headaches. Serious side effects may include increased risk of infections due to immunosuppression, liver enzyme abnormalities, and gastrointestinal perforations.
Pharmacokinetics[edit | edit source]
Levilimab is administered via subcutaneous injection. It has a long half-life, allowing for less frequent dosing compared to some other biologics. The drug is metabolized through the reticuloendothelial system and is not significantly excreted through the kidneys or liver.
Regulatory Status[edit | edit source]
Levilimab is approved for use in several countries for specific indications. Its approval status may vary depending on the regulatory body and the specific condition being treated.
Research and Development[edit | edit source]
Ongoing research is exploring the use of levilimab in other inflammatory and autoimmune conditions. Clinical trials are assessing its efficacy and safety in broader patient populations.
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
